Trials / Conditions / Unresectable Solid Tumor

Unresectable Solid Tumor

14 registered clinical trials studyying Unresectable Solid Tumor — 12 currently recruiting.

Status	Trial	Sponsor	Phase
Not Yet Recruiting	Study of RGT-490 in Patients With PIK3CA-Mutated Advanced Solid Tumors NCT07524322	Regor Pharmaceuticals Inc.	Phase 1
Not Yet Recruiting	CSB-321 Ph 1 in Immunotherapy for the Treatment of Cancer NCT07057349	Cytosite Biopharma Inc.	Phase 1
Recruiting	A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation NCT06778863	Clasp Therapeutics, Inc.	Phase 1
Recruiting	COLDFIRE-III Trial: Efficacy of Irreversible Electroporation and Stereotactic Body Radiotherapy for Perivascul NCT06185556	Amsterdam UMC, location VUmc	Phase 2 / Phase 3
Recruiting	Pemigatinib + Afatinib in Advanced Refractory Solid Tumors NCT06302621	Massachusetts General Hospital	Phase 1
Recruiting	A Study Evaluating FMC-376 in Participants With KRAS G12C Mutated Solid Tumors NCT06244771	Frontier Medicines Corporation	Phase 1 / Phase 2
Recruiting	A Dose Escalation and Expansion Study of [177Lu]Lu-SN201 in Participants With Advanced Cancer NCT06184035	Spago Nanomedical AB	Phase 1 / Phase 2
Recruiting	Palliative Spatially Fractionated (GRID) Radiotherapy Using Intensity Modulated Proton Therapy NCT05831579	Washington University School of Medicine	N/A
Completed	First-in-Human Study of RLY-5836 in Advanced Breast Cancer and Other Solid Tumors NCT05759949	Relay Therapeutics, Inc.	Phase 1
Recruiting	Avapritinib in the Treatment of Unresectable or Recurrent Metastatic GIST Non-exon18 Mutations of PDGFRA NCT05461664	Xinhua Zhang, MD	—
Recruiting	A Multicenter Study of Avapritinib Efficacy and Safety of Metastatic or Unresectable Gastrointestinal Stromal NCT05464875	Xinhua Zhang, MD	—
Recruiting	First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advance NCT05216432	Relay Therapeutics, Inc.	Phase 1
Completed	A Study of RC118 in Patients With Locally Advanced Unresectable/Metastatic Solid Tumours NCT04914117	RemeGen Co., Ltd.	Phase 1
Recruiting	A Beta-only IL-2 ImmunoTherapY Study NCT05086692	Medicenna Therapeutics, Inc.	Phase 1 / Phase 2